Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

enzastaurin

- PMLiVE

Jardiance is first diabetes drug to improve CV outcomes

Lilly/Boehringer drug could gain market share boost from new data

Boehringer Ingelheim headquarters

Boehringer returns to growth in first half

German firm back on track after a tough sales period

Lilly brings Glucagon app to Android devices

Follows app's 2012 debut in iPhone version

Eli Lilly HQ

Lilly expands its San Diego biotech centre

Movewill create over 100 new drug discovery jobs

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

- PMLiVE

AbbVie and C2N take tau antibody into clinic

Treatment being assessed for a progressive neurodegenerative disorder

Eli Lilly HQ

Lilly closes on US approval of lung cancer drug necitumumab

Indication for NSCLC looking likely after informal panel poll

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Eli Lilly HQ

Lilly and Incyte’s baricitinib aces phase III trials

Supports its potential as a therapy for rheumatoid arthritis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links